Status:
RECRUITING
Italian Registry of Allergen ImmunoTherapy
Lead Sponsor:
Società Italiana di Allergologia, Asma e Immunologia Clinica
Collaborating Sponsors:
Società Italiana di Allergologia e Immunologia Pediatrica (SIAIP)
Conditions:
Allergic Respiratory Disease
Eligibility:
All Genders
1+ years
Brief Summary
RIAIT (Italian Registry of Allergy Immunotherapy) is a multicenter observational study that aims to prospectively collect the most extensive data available on Italian patients using AIT for respirator...
Detailed Description
Objectives include: * Evaluate short and long-term real-life effectiveness and safety of AIT overall, in specific patient groups' phenotypes and with specific AIT products. * Evaluate the pertinence ...
Eligibility Criteria
Inclusion
- Age ≥ 1 year
- Confirmed diagnosis of allergic rhinoconjunctivitis and/or allergic asthma according to EAACI 2019 guidelines.
- Having been followed by the recruiting center for at least one month: this is considered necessary to establish that the patients are truly affected by allergic respiratory disease and are eligible for allergen-specific immunotherapy; in this period, screening tests are carried out to exclude and/or confirm concomitant diseases (comorbidities). In fact, according to the aforementioned EAACI guidelines, a patient can be defined as truly eligible for allergen-specific immunotherapy only after a preliminary phase in which the patient is treated with symptomatic therapy; this observation period allows a correct evaluation of the real adherence and response to therapy, as well as the identification and appropriate treatment of any comorbidity and the possible elimination of aggravating factors.
- Having received the prescription of any of the available AIT products in Italy, irrespectively of the selected allergens and the administration route and schedule.
Exclusion
- There will no be exclusion criteria, in order to allow a real-life vision of the characteristics of these patients eligible for or treated with allergen-specific immunotherapy.
Key Trial Info
Start Date :
May 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2035
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT06499480
Start Date
May 1 2024
End Date
December 31 2035
Last Update
March 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy
Rozzano, Milano, Italy, 20089
2
Azienda Ospedaliera Universitaria Istituto di Ricovero e Cura a Carattere Scientifico
Florence, Italy